Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00721669 · ClinicalTrials.gov registry record · Phase 1
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by ImmunoGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT00721669: Completed Phase 1 study of Solid Tumor, sponsored by ImmunoGen.
NCT00721669 is a Phase 1 study of Solid Tumor that has completed, run by ImmunoGen. The registered enrollment target is 60 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (73% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00721669, a Phase 1 study of Solid Tumor, has completed, sponsored by ImmunoGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
Primary objective is to evaluate the safety and PK of IMGN388
Conditions Studied
Interventions
- DRUG IMGN388
Study Locations (3)
Florida
- Florida Cancer Specialists - Fort Myers
Oklahoma
- University of Oklahoma - Oklahoma City
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
What the finished NCT00721669 record still lists
NCT00721669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which IMGN388 is the first listed.
NCT00721669 reports a single indexed study location in Florida, Oklahoma, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00721669 about?
NCT00721669 is a clinical study titled "A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors". Primary objective is to evaluate the safety and PK of IMGN388
What is the current status of trial NCT00721669?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2008-06. Estimated completion is 2012-12.
What conditions does trial NCT00721669 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT00721669?
The interventions under investigation include: IMGN388 (DRUG).
Who is sponsoring clinical trial NCT00721669?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00721669 being conducted?
This trial has 3 study locations across Florida, Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00721669's enrollment target sits among peer trials
60 110th of 196 higher than 85 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia